title: Clinical management of Von Hippel-Lindau (VHL) disease.
abstract: Von Hippel-Lindau (VHL) disease is an autosomal, dominant inherited tumour syndrome with an estimated prevalence of 2-3 per 100,000 persons. A germline mutation in the VHL gene predisposes carriers to tumours in multiple organs. These tumours may include haemangioblastoma in the retina and central nervous system (CNS), renal cell carcinoma, phaeochromocytoma, islet cell tumours of the pancreas, and endolymphatic sac tumours, as well as cysts and cystadenoma in the kidney, pancreas, epididymis and broad ligament. Penetrance of VHL disease is high, most carriers of a VHL germline mutation develop one or more tumours by the age of 60 years. The most common symptoms include: loss of vision, raised intracranial pressure, neurological deficits, paroxysmal raised blood pressure and local pain. At present, metastases from renal cell carcinoma and neurological complications from cerebellar haemangioblastoma are the most common causes of death. However, it is anticipated that intensive radiological and clinical monitoring, and advanced operation techniques will reduce both morbidity and mortality in patients with VHL disease.
authors.affiliation: Department of Internal Medicine, University Medical Center Utrecht, PO Box 85090, 3508 AB, Utrecht, The Netherlands.
authors.forename: F J
authors.initials: FJ
authors.lastname: Hes
authors.forename: R B
authors.initials: RB
authors.lastname: van der Luijt
authors.forename: C J
authors.initials: CJ
authors.lastname: Lips
mesh_terms: D006801:Humans; D006623:von Hippel-Lindau Disease / Q000175:diagnosis / Q000628:therapy